These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35335921)

  • 1. The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models.
    Sui D; Meng X; Li C; Tang X; Qin Y; Zhang N; Ding J; Liu X; Deng Y; Song Y
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
    Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
    Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
    Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selection of animal models influences the assessment of anti-tumor efficacy: promising sialic acid-conjugate modified liposomes demonstrate remarkable therapeutic effects in diverse mouse strains.
    Wei L; Lin L; Wang J; Guan X; Li W; Gui Y; Liao S; Wang M; Li J; Deng Y; Song Y
    Drug Deliv Transl Res; 2024 Jul; 14(7):1794-1809. PubMed ID: 38165530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of TAMs with freeze-dried monosialotetrahexosylganglioside and sialic acid-octadecylamine co-modified liposomes remodels the tumor microenvironment and enhances anti-tumor activity.
    Wei L; Zhao D; Sun W; Lin L; Sui D; Li W; Gui Y; Wang J; Deng Y; Song Y
    Eur J Pharm Biopharm; 2023 Mar; 184():50-61. PubMed ID: 36682511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
    Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
    Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives.
    Song Y; She Z; Huang Z; Wang S; Liu X; Zhang Q; Sun J; Di D; Deng Y
    Drug Deliv Transl Res; 2022 Mar; 12(3):647-661. PubMed ID: 33928513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity.
    Sui D; Tang X; Ding J; Wang Y; Qin Y; Zhang N; Liu X; Deng Y; Song Y
    Int J Pharm; 2021 Jun; 602():120552. PubMed ID: 33798685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
    Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
    Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid.
    Mayhew EG; Lasic D; Babbar S; Martin FJ
    Int J Cancer; 1992 May; 51(2):302-9. PubMed ID: 1568796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate.
    Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y
    Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.
    She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y
    Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new modality in targeted delivery of epirubicin for tumor theranosis based on PEGylated silver nanoparticles: Design, radiolabeling and bioevaluation.
    Abdel-Hameed ME; Farrag NS; Aglan H; Amin AM; Mahdy MA
    Int J Pharm; 2022 Dec; 629():122358. PubMed ID: 36332832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells.
    Gupta Y; Jain A; Jain P; Jain SK
    J Drug Target; 2007 Apr; 15(3):231-40. PubMed ID: 17454361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.